Tel: 0086‐411‐8479609‐801 Fax: 0086‐411‐84799629
E‐mail: sally@bitlifesciences.com
Section 1‐1: Breaking Research in Protein Science |
Session 1‐3‐3: Protein Post‐translational Modification and Activity Regulation |
Chapter 2: Proteomics and Metaproteomics
Section 2‐1: Innovative Proteome Technologies
Section 2‐2: Bioinformatics and Proteomics and Metaproteomics
Section 2‐3: Animal Models in Proteomics
Section 2‐4: Nanoproteomics, Chip and Array Technologies in Proteomics
Section 2‐5: MS, Imaging MS and MALDI‐TOF in Cancer Proteomics
Section 2‐6: Cancer Proteomics
Section 2‐7: Human Proteome Technologies and Cancer Research Section 2‐8: Metalloproteomics |
Section 2‐9: Neuroproteomics
Section 2‐10: Plant Proteomic
Section 2‐11: Functional and Structural Proteomics of Glycoproteins
Section 2‐12: Metaproteomics of Natural Microbial Communities
Section 2‐13: Oral Metaproteomics and Clinical Significance
Section 2‐14: Gut/GI Tract Microbiota and Metaproteomics
Section 2‐15: Metaproteomics and Novel Enzyme Discovery |
Chapter 3: Human Diseases and Protein Discovery
Section 3‐1: Protein Networks in Disease
Section 3‐2: Protein‐protein Interactions and Diseases
Section 3‐3: Protein Misfolding and Human Diseases
Section 3‐4: Protein Folds in Infectious Diseases
Section 3‐5: Intrinsically Disordered Proteins
Section 3‐6: Protein Misfolding and Neurodiseases
Section 3‐7: Proteins in Apoptosis and Autophagy
Section 3‐8: Signal Transductions and Diseases
Section 3‐9: Heat Shock Proteins and Diseases
Section 3‐10: Metabolic Signalling and Disease
Section 3‐11: Amyloids and Disease
Section 4‐1: Protein Drug Discovery Technology
Session 4‐1‐1: Discovery of Emerging Protein Therapeutic Targets
Session 4‐1‐2: Protein Structure, Modeling, and Fragment‐based Drug Discovery
Session 4‐1‐3: Design Drugs Targeting Protein‐protein Interactions
Session 4‐1‐4: Transmembrane and Fusion Proteins Based Drug Discovery
Session 4‐1‐5: Protein Surface Recognition Approaches for Drug Discovery
Session 4‐1‐6: Plasma Protein Therapeutics
Session 4‐1‐7: Anticancer Protein Therapeutics
Session 4‐1‐8: Protein Therapeutics for Immunologic & Inflammatory Diseases
Session 4‐1‐9: DMPK and ADMET of Protein Drugs
Section 4‐2: Protein Biomarkers
Session 4‐2‐1: Protein Biomarker Discovery and Validation for Diagnosis and Treatment
Session 4‐2‐2: Toxicity Biomarkers and Biomarkers Assay Development
Session 4‐2‐3: Protein Biomarkers for Cancers
Session 4‐2‐4: Protein Biomarkers for Diseases:
Cardiovascular, CNS, Inflammation and Immunology
Session 4‐2‐5: Protein Biomarkers for Personalized
Medicine
Section 4‐3: Cytokines
Session 4‐3‐1: New Landscape of Cytokine Drug Discovery
from Targets/Receptors to Screening Assays
Session 4‐3‐2: Novel Drugs Targeting Cytokine Storm
Session 4‐3‐3: Cancer Drug Discovery Targeting Cytokine in the Genesis
Session 4‐3‐4: Cytokine Receptors and Implications
Session 4‐3‐5: Anti‐inflammatory Cytokine Antagonists
Session 4‐3‐6: Plasma Cytokines, Diseases and Diagnosis
Session 4‐3‐7: Cysteine‐knote Cytokines
Section 4‐4: Kinases
Session 4‐4‐1: Kinase Structure, Signaling Pathways,
Network and Selectivity
Session 4‐4‐2: Computer Aided and Structure Based Kinase Drug Design
Session 4‐4‐3: Oncology, Inflammation & Autoimmune
Kinase Inhibitors
Session 4‐4‐4: Drugs Targeting PI3‐Kinases, and AKT/MAP Kinase |
Session 4‐4‐5: Protein Kinase CK2
Session 4‐4‐6: Kinases for CNS Indications
Session 4‐4‐7: Screening& Monitoring DMPK and Tox of Kinase Inhibitors
Session 4‐4‐8: Overcome Drug‐resistant Kinase Inhibitors
Section 4‐5: NF‐kB based Drug Discovery and Clinical Significance
Session 4‐5‐1: Structure and Molecular Basis of NF‐kB Session 4‐5‐2: NF‐κB Signaling Pathway and Regulations
Session 4‐5‐3: NF‐κB as Drug Targets of Immunological Diseases
Session 4‐5‐4: NF‐κB as Drug Targets of CNS & Neurological Disorders
Session 4‐5‐5: Anticancer Drugs Targeting NF‐κB
Session 4‐5‐6: Anti‐inflammatory Drug Discovery Targeting NF‐kB
Session 4‐5‐7: NF‐kB based Drug Resistant Antibiotic Discovery
Session 4‐5‐8: Gene Therapy Targeting NF‐kB
Session 4‐5‐9: NF‐κB to Chronic Liver Disease
Session 4‐5‐10: NF‐κB as Biomarkers and Molecular Diagnosis
Section 4‐6: Protein Therapeutics Formulation and Delivery
Session 4‐6‐1: How to Overcome Protein Degradations for Longer Half‐life
Session 4‐6‐2: PEGylated Protein Drugs
Session 4‐6‐3: Methods Improving the Quality of Protein Formulation
Session 4‐6‐4: Transdermal Protein Delivery Technology
Session 4‐6‐5: Oral and Nasal Protein Delivery Technology
Session 4‐6‐6: Pulmonary Protein Delivery Technology
Session 4‐6‐7: Medical Devices for Protein Drug Delivery
Session 4‐6‐8: Optimizing Biologics Formulation and Industrial Process
Session 4‐6‐9: Formulated Protein Characterization and QA/QC |
Chapter 5: Non ‐ Human Protein R & D
Part 2: Peptide Chemistry and Biology
Chapter 6: Peptide Science
Chapter 7: Peptide Chemistry and Synthetic Methods
Part 3: Protein Industry